Latest common stock for FRTX: $60K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
Fresh Tracks Therapeutics (FRTX) currently reports a common stock of $60K as of December 2023. That compares with $3M in the prior-year period — down 98.0% year over year. Use the charts on this page to explore Fresh Tracks Therapeutics's common stock history and peer comparisons.
Fresh Tracks Therapeutics's common stock decreased from $3M to $60K — a 98.0% year-over-year decrease (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Fresh Tracks Therapeutics reported $60K in common stock as of December 2023. That compares with $3M in the prior-year period — down 98.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current common stock of $60K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Fresh Tracks Therapeutics, and consider following FRTX for alerts when major investors trade the stock.
Fresh Tracks Therapeutics is classified in the Healthcare sector. On common stock, it currently shows $60K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FRTX with unrelated industries.